Priovant

Priovant Therapeutics is a clinical-stage biotechnology company focused on providing novel therapies for autoimmune diseases with the highest morbidity and mortality. We are developing oral brepocitinib, a potential first-in-class TYK2 and JAK1 dual inhibitor, for various severe autoimmune indications, offering new treatment options for patients inadequately served by existing therapies.